Vera Bril

List of Publications by Year
in descending order

279 papers	16,676 citations	26630 56 h-index	18647 119 g-index
281 all docs	281 docs citations	281 times ranked	10351 citing authors

#	Article	IF	Citations
1	Diabetic Neuropathies. Diabetes Care, 2005, 28, 956-962.	8.6	1,599
2	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 136-154.	8.6	1,452
3	Diabetic neuropathy. Nature Reviews Disease Primers, 2019, 5, 41.	30.5	692
4	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurology, The, 2008, 7, 136-144.	10.2	582
5	Evidence-based guideline: Treatment of painful diabetic neuropathy [RETIRED]. Neurology, 2011, 76, 1758-1765.	1.1	561
6	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
7	Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic. Diabetes Care, 2001, 24, 250-256.	8.6	454
8	Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study. Brain, 1996, 119, 1055-1066.	7.6	392
9	Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes/Metabolism Research and Reviews, 2011, 27, 620-628.	4.0	359
10	Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care, 2002, 25, 2048-2052.	8.6	341
11	Regeneration and Repair of Myelinated Fibers in Sural-Nerve Biopsy Specimens from Patients with Diabetic Neuropathy Treated with Sorbinil. New England Journal of Medicine, 1988, 319, 548-555.	27.0	321
12	Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology, 2011, 76, 2017-2023.	1.1	273
13	IV immunoglobulin in patients with myasthenia gravis. Neurology, 2007, 68, 837-841.	1.1	255
14	Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy. Diabetes Care, 2002, 25, 565-569.	8.6	241
15	Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.. Journal of Clinical Investigation, 1988, 81, 349-364.	8.2	197
16	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536.	10.2	194
17	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	10.2	193
18	Detection of Diabetic Sensorimotor Polyneuropathy by Corneal Confocal Microscopy in Type 1 Diabetes. Diabetes Care, 2012, 35, 821-828.	8.6	177

#	Article	IF	Citations
19	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 2019, 92, e2661-e2673.	1.1	169
20	Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics, 2005, 27, 1278-1294.	2.5	162
21	Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C Î²-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clinical Therapeutics, 2005, 27, 1164-1180.	2.5	161
22	Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabetic Medicine, 2009, 26, 240-246.	2.3	153
23	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. Diabetes Care, 2015, 38, 838-843.	8.6	150
24	Diabetic neuropathy: a review emphasizing diagnostic methods. Clinical Neurophysiology, 2003, 114, 1167-1175.	1.5	139
25	Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. Diabetic Medicine, 2011, 28, 1253-1260.	2.3	135
26	Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2006, 29, 68-72.	8.6	126
27	The genomic landscape of schwannoma. Nature Genetics, 2016, 48, 1339-1348.	21.4	124
28	Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Research and Clinical Practice, 2001, 54, 115-128.	2.8	123
29	NIS-LL: The Primary Measurement Scale for Clinical Trial Endpoints in Diabetic Peripheral Neuropathy. European Neurology, 1999, 41, 8-13.	1.4	120
30	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
31	Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients?. Diabetes Care, 2014, 37, 1418-1424.	8.6	105
32	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia, 2018, 61, 1856-1861.	6.3	103
33	Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Archives of Neurology, 2010, 67, 802.	4.5	99
34	Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis. Neurology, 2021, 96, e853-e865.	1.1	97
35	Long-Term Clinical Outcome After Transcervical Thymectomy for Myasthenia Gravis. Annals of Thoracic Surgery, 1998, 65, 1520-1522.	1.3	96
36	Electrophysiological monitoring in clinical trials. , 1998, 21, 1368-1373.		95

#	Article	IF	Citations
37	Effect of omega-3 supplementation on neuropathy in type 1 diabetes. Neurology, 2017, 88, 2294-2301.	1.1	95
38	Can Ultrasound of the Tibial Nerve Detect Diabetic Peripheral Neuropathy?. Diabetes Care, 2012, 35, 2575-2579.	8.6	92
39	Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disorders, 2016, 26, 41-46.	0.6	90
40	Changing outcome in inflammatory neuropathies. Neurology, 2014, 83, 2124-2132.	1.1	89
41	Aldose Reductase Inhibition by AS-3201 in Sural Nerve From Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2004, 27, 2369-2375.	8.6	88
42	Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2009, 32, 1256-1260.	8.6	88
43	Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology, 2018, 90, e1425-e1434.	1.1	86
44	International clinimetric evaluation of the MGâ€QOL15, resulting in slight revision and subsequent validation of the MGâ€QOL15r. Muscle and Nerve, 2016, 54, 1015-1022.	2.2	85
45	Structure-Function Relationship Between Corneal Nerves and Conventional Small-Fiber Tests in Type 1 Diabetes. Diabetes Care, 2013, 36, 2748-2755.	8.6	83
46	Impact of minimally invasive trans-cervical thymectomy on outcome in patients with myasthenia gravis. European Journal of Cardio-thoracic Surgery, 2003, 24, 677-683.	1.4	81
47	Prediction of Incident Diabetic Neuropathy Using the Monofilament Examination. Diabetes Care, 2010, 33, 1549-1554.	8.6	80
48	Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. Journal of Diabetes and Its Complications, 1995, 9, 170-176.	2.3	73
49	Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy. PLoS ONE, 2014, 9, e86515.	2.5	72
50	Low-Intensity Laser Therapy for Painful Symptoms of Diabetic Sensorimotor Polyneuropathy: A controlled trial. Diabetes Care, 2004, 27, 921-924.	8.6	69
51	Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor. Muscle and Nerve, 1993, 16, 1293-1301.	2.2	68
52	Prognostic significance of thymomas in patients with myasthenia gravis. Annals of Thoracic Surgery, 2002, 74, 1658-1662.	1.3	66
53	Reference values for ultrasonograpy of peripheral nerves. Muscle and Nerve, 2016, 53, 538-544.	2.2	66
54	Peripheral nerve highâ€resolution ultrasound in diabetes. Muscle and Nerve, 2017, 55, 171-178.	2.2	64

#	Article	IF	Citations
55	Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Neurology, 2022, 98, 31-43.	1.1	64
56	Conduction Slowing in Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2013, 36, 3684-3690.	8.6	63
57	Variables associated with corneal confocal microscopy parameters in healthy volunteers: implications for diabetic neuropathy screening. Diabetic Medicine, 2012, 29, e297-303.	2.3	62
58	Heart Rate Variability Measurement in Diabetic Neuropathy: Review of Methods. Diabetes Technology and Therapeutics, 2001, 3, 63-76.	4.4	59
59	Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. PLoS ONE, 2013, 8, e58783.	2.5	58
60	InÂVivo Corneal Confocal Microscopy and Prediction ofÂFuture-Incident Neuropathy in Type 1 Diabetes: AÂPreliminaryÂLongitudinal Analysis. Canadian Journal of Diabetes, 2015, 39, 390-397.	0.8	57
61	Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. Muscle and Nerve, 2005, 32, 619-625.	2.2	56
62	Electrophysiologic correlations with clinical outcomes in CIDP. Muscle and Nerve, 2010, 42, 492-497.	2.2	56
63	Glycemic Control Is Related to the Morphological Severity of Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2001, 24, 748-752.	8.6	54
64	Treatments for diabetic neuropathy. Journal of the Peripheral Nervous System, 2012, 17, 22-27.	3.1	54
65	Novel Treatments in Myasthenia Gravis. Frontiers in Neurology, 2020, 11, 538.	2.4	54
66	Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2006, 29, 2023-2027.	8.6	53
67	Single-fiber electromyography in diabetic peripheral polyneuropathy. , 1996, 19, 2-9.		52
68	Comparison of a Neurothesiometer and Vibration in Measuring Vibration Perception Thresholds and Relationship to Nerve Conduction Studies. Diabetes Care, 1997, 20, 1360-1362.	8.6	50
69	Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial. Muscle and Nerve, 2014, 49, 661-665.	2.2	50
70	Glycemic Control Is Related to the Electrophysiologic Severity of Diabetic Peripheral Sensorimotor Polyneuropathy. Diabetes Care, 1998, 21, 1749-1752.	8.6	49
71	Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabetic Medicine, 2002, 19, 661-666.	2.3	46
72	The Quantitative Myasthenia Gravis Score. Journal of Clinical Neuromuscular Disease, 2012, 13, 201-205.	0.7	46

#	Article	IF	Citations
73	A Comparison of the Effectiveness of Intravenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2008, 9, 352-355.	0.7	44
74	Development and validation of the Myasthenia Gravis Impairment Index. Neurology, 2016, 87, 879-886.	1.1	43
75	The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. Journal of Diabetes and Its Complications, 2016, 30, 1401-1407.	2.3	43
76	Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments. Diabetes Care, 2004, 27, 1674-1679.	8.6	42
77	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle and Nerve, 2009, 39, 448-455.	2.2	42
78	Midbrain asterixis. Annals of Neurology, 1979, 6, 362-364.	5.3	41
79	Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Reduces Sorbitol Levels and Improves Motor Nerve Conduction Velocity in Streptozotocin-Diabetic Rats. Journal of Pharmacological Sciences, 2008, 107, 231-237.	2.5	41
80	Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. Journal of the Peripheral Nervous System, 2010, 15, 208-215.	3.1	41
81	Incat disability score: A critical analysis of its measurement properties. Muscle and Nerve, 2014, 50, 164-169.	2.2	41
82	Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 189-202.	10.2	41
83	Rapid Corneal Nerve Fiber Loss: A Marker of Diabetic Neuropathy Onset and Progression. Diabetes Care, 2020, 43, 1829-1835.	8.6	40
84	The long-term clinical outcome of myasthenia gravis in patients with thymoma. Neurology, 1998, 51, 1198-1200.	1.1	39
85	Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats. Journal of Pharmacological Sciences, 2008, 107, 340-348.	2.5	39
86	Complications of Sural Nerve Biopsy in Diabetic versus Non-Diabetic Patients. Canadian Journal of Neurological Sciences, 1994, 21, 34-37.	0.5	38
87	Sex differences in neuropathic pain intensity in diabetes. Journal of the Neurological Sciences, 2018, 388, 103-106.	0.6	38
88	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight, 2018, 3, .	5.0	38
89	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. PLoS ONE, 2015, 10, e0142309.	2.5	37
90	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1318-1324.	2.3	37

#	Article	IF	Citations
91	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 2570-2578.	8.6	37
92	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e590.	6.0	37
93	Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs, 2022, 82, 865-887.	10.9	36
94	Myasthenia Gravis Impairment Index. Neurology, 2017, 89, 2357-2364.	1.1	35
95	Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle and Nerve, 2018, 58, 197-203.	2.2	33
96	Patient-acceptable symptom states in myasthenia gravis. Neurology, 2020, 95, e1617-e1628.	1.1	33
97	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. PLoS ONE, 2016, 11, e0165731.	2.5	33
98	Diagnosis and management of diabetic neuropathy. Current Diabetes Reports, 2002, 2, 495-500.	4.2	32
99	Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle and Nerve, 2013, 47, 510-514.	2.2	32
100	Electrophysiologic testing in diabetic neuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 235-248.	1.8	32
101	Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. Expert Review of Clinical Immunology, 2014, 10, 1659-1665.	3.0	31
102	A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfusion and Apheresis Science, 2005, 33, 317-324.	1.0	30
103	Impairment measures versus inflammatory <scp>RODS</scp> in <scp>GBS</scp> and <scp>CIDP</scp>: a responsiveness comparison. Journal of the Peripheral Nervous System, 2015, 20, 289-295.	3.1	30
104	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes â€“ An Observational Study. PLoS ONE, 2014, 9, e89344.	2.5	29
105	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovascular Diabetology, 2016, 15, 14.	6.8	29
106	Role of Electrophysiological Studies in Diabetic Neuropathy. Canadian Journal of Neurological Sciences, 1994, 21, S8-S12.	0.5	28
107	Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. Muscle and Nerve, 2002, 25, 212-217.	2.2	28
108	A Comparison of Electrodiagnostic Tests in Ocular Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2005, 6, 109-113.	0.7	28

#	Article	IF	Citations
109	Sensitivity of repetitive facialâ€nerve stimulation in patients with myasthenia gravis. Muscle and Nerve, 2006, 33, 694-696.	2.2	28
110	Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 94-97.	1.9	28
111	Grip strength comparison in immuneâ€mediated neuropathies: Vigorimeter vs. Jamar. Journal of the Peripheral Nervous System, 2015, 20, 269-276.	3.1	28
112	Peripheral Nerve Ultrasound in Small Fiber Polyneuropathy. Ultrasound in Medicine and Biology, 2015, 41, 2820-2826.	1.5	28
113	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. Diabetes Care, 2021, 44, 2107-2114.	8.6	28
114	Shortâ€term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1â€year placebo cohort analysis. Diabetic Medicine, 2010, 27, 1271-1279.	2.3	27
115	Comparing the <scp>NIS</scp> vs. <scp>MRC</scp> and <scp>INCAT</scp> sensory scale through Rasch analyses. Journal of the Peripheral Nervous System, 2015, 20, 277-288.	3.1	27
116	Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle and Nerve, 2017, 55, 166-170.	2.2	27
117	The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle and Nerve, 2018, 57, 240-244.	2.2	27
118	Chronic immunoglobulin maintenance therapy in myasthenia gravis. European Journal of Neurology, 2021, 28, 639-646.	3.3	27
119	Limits of the sympathetic skin response in patients with diabetic polyneuropathy. Muscle and Nerve, 2000, 23, 1427-1430.	2.2	26
120	Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study. Orphanet Journal of Rare Diseases, 2014, 9, 214.	2.7	26
121	Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research. Journal of Diabetes and Its Complications, 2017, 31, 1066-1073.	2.3	26
122	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 298-307.	4.4	25
123	Comparison of sensory testing on different toe surfaces: Implications for neuropathy screening. Neurology, 2002, 59, 611-613.	1.1	24
124	IVIG Treatment for Myasthenia Gravis. Annals of the New York Academy of Sciences, 2008, 1132, 264-270.	3.8	23
125	Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. European Journal of Neurology, 2018, 25, 484-490.	3.3	23
126	A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. European Neurology, 2019, 81, 223-230.	1.4	23

#	Article	IF	Citations
127	A Conceptual Framework for Evaluating Impairments in Myasthenia Gravis. PLoS ONE, 2014, 9, e98089.	2.5	23
128	Diabetic Neuropathy and Axon Reflex-Mediated Neurogenic Vasodilatation in Type 1 Diabetes. PLoS ONE, 2012, 7, e34807.	2.5	22
129	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2018, 32, 660-664.	2.3	22
130	Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2000, 23, 206-210.	2.2	21
131	IVIG and PLEX in the treatment of myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 1-6.	3.8	21
132	Comparison of diabetes patients with â€œdemyelinatingâ€•diabetic sensorimotor polyneuropathy to those diagnosed with <scp>CIDP</scp>. Brain and Behavior, 2013, 3, 656-663.	2.2	21
133	Prevalence of Muscle Cramps in Patients With Diabetes: Table 1. Diabetes Care, 2014, 37, e17-e18.	8.6	21
134	Safety and efficacy of ranirestat in patients with mildâ€toâ€moderate diabetic sensorimotor polyneuropathy. Journal of the Peripheral Nervous System, 2015, 20, 363-371.	3.1	21
135	Diabetic Neuropathies. Seminars in Neurology, 2015, 35, 424-430.	1.4	21
136	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials, 2016, 17, 345.	1.6	21
137	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107324.	2.3	21
138	The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations. PLoS ONE, 2017, 12, e0171597.	2.5	21
139	Followâ€up nerve conduction studies in CIDP after treatment with IGIVâ€C: Comparison of patients with and without subsequent relapse. Muscle and Nerve, 2015, 52, 498-502.	2.2	20
140	Canadian Administrative Health Data Can Identify Patients with Myasthenia Gravis. Neuroepidemiology, 2015, 44, 108-113.	2.3	20
141	Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy. Muscle and Nerve, 2016, 54, 856-863.	2.2	20
142	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 716-722.	2.3	20
143	Current pharmacotherapeutic options for myasthenia gravis. Expert Opinion on Pharmacotherapy, 2019, 20, 2295-2303.	1.8	20
144	Muscle thickness measured by ultrasound is reduced in neuromuscular disorders and correlates with clinical and electrophysiological findings. Muscle and Nerve, 2019, 60, 687-692.	2.2	20

#	Article	IF	Citations
145	Neuropathy. Canadian Journal of Diabetes, 2013, 37, S142-S144.	0.8	19
146	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. Diabetes Care, 2016, 39, e67-e68.	8.6	19
147	Electrophysiological testing is correlated with myasthenia gravis severity. Muscle and Nerve, 2017, 56, 445-448.	2.2	19
148	Status of Current Clinical Trials in Diabetic Polyneuropathy. Canadian Journal of Neurological Sciences, 2001, 28, 191-198.	0.5	18
149	Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle and Nerve, 2012, 45, 648-652.	2.2	18
150	Performance of individual items of the quantitative myasthenia gravis score. Neuromuscular Disorders, 2013, 23, 413-417.	0.6	18
151	Frequent laboratory abnormalities in CIDP patients. Muscle and Nerve, 2016, 53, 862-865.	2.2	18
152	Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neuro-Oncology Advances, 2020, 2, i141-i149.	0.7	18
153	Construction and validation of the chronic acquired polyneuropathy patientâ€reported index (CAPâ€PRI): A diseaseâ€specific, healthâ€related qualityâ€ofâ€life instrument. Muscle and Nerve, 2016, 54, 9-17.	2.2	17
154	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	8.6	17
155	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
156	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2019, 42, 273-280.	8.6	16
157	Myasthenia gravis in pregnancy: Systematic review and case series. Obstetric Medicine, 2022, 15, 108-117.	1.1	16
158	Suralâ€toâ€radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. Muscle and Nerve, 2012, 45, 126-127.	2.2	15
159	The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. Journal of Diabetes and Its Complications, 2013, 27, 240-242.	2.3	15
160	Using in vivo corneal confocal microscopy to identify diabetic sensorimotor polyneuropathy risk profiles in patients with type 1 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000251.	2.8	15
161	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. American Journal of Kidney Diseases, 2019, 73, 786-796.	1.9	15
162	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 575-583.	4.4	15

#	Article	IF	Citations
163	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. Journal of the Peripheral Nervous System, 2020, 25, 230-237.	3.1	15
164	Congenital myasthenic syndromeâ€“associated agrin variants affect clustering of acetylcholine receptors in a domain-specific manner. JCI Insight, 2020, 5, .	5.0	15
165	Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle and Nerve, 2016, 53, 872-876.	2.2	14
166	Muscle biopsy technical safety and quality using a self-contained, vacuum-assisted biopsy technique. Neuromuscular Disorders, 2018, 28, 450-453.	0.6	14
167	Chronic stress, depression and personality type in patients with myasthenia gravis. European Journal of Neurology, 2020, 27, 204-209.	3.3	14
168	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetologia, 2017, 60, 2529-2531.	6.3	14
169	Evaluation of Proxy Tests for SFSN: Evidence for Mixed Small and Large Fiber Dysfunction. PLoS ONE, 2012, 7, e42208.	2.5	14
170	Measurement of Cooling Detection Thresholds for Identification of Diabetic Sensorimotor Polyneuropathy in Type 1 Diabetes. PLoS ONE, 2014, 9, e106995.	2.5	14
171	Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients. Journal of Neurology, 2014, 261, 1485-1491.	3.6	13
172	Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. Expert Review of Clinical Immunology, 2015, 11, 537-546.	3.0	13
173	Ultrasound in Neuromuscular Disorders. Journal of Clinical Neurophysiology, 2016, 33, 80-85.	1.7	13
174	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. Journal of the Neurological Sciences, 2017, 372, 223-227.	0.6	13
175	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 831-839.	8.6	13
176	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
177	Quantitative sonographic evaluation of muscle thickness and fasciculation prevalence in healthy subjects. Muscle and Nerve, 2020, 61, 234-238.	2.2	13
178	Clinical profile and impact of comorbidities in patients with veryâ€lateâ€onset myasthenia gravis. Muscle and Nerve, 2021, 64, 462-466.	2.2	13
179	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. PLoS ONE, 2018, 13, e0196647.	2.5	13
180	Sural Nerve Sorbitol in Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2004, 27, 1160-1163.	8.6	12

#	Article	IF	Citations
181	Surrogate therapeutic outcome measures in patients with myasthenia gravis. Muscle and Nerve, 2008, 37, 172-176.	2.2	12
182	Improvement of Motor Nerve Conduction Velocity in Diabetic Rats Requires Normalization of the Polyol Pathway Metabolites Flux. Journal of Pharmacological Sciences, 2009, 109, 203-210.	2.5	12
183	Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. Diabetes Research and Clinical Practice, 2012, 97, e37-e40.	2.8	12
184	Neuromuscular Complications of Diabetes Mellitus. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 531-544.	0.8	12
185	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. Journal of the Neurological Sciences, 2017, 379, 94-98.	0.6	12
186	Estimating GFR by Serum Creatinine, Cystatin C, and Î²2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. Kidney International Reports, 2019, 4, 786-796.	0.8	12
187	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1388-1398.	4.4	12
188	EQâ€5Dâ€5L and SFâ€6D health utility index scores in patients with myasthenia gravis. European Journal of Neurology, 2019, 26, 452-459.	3.3	12
189	Emerging Therapies for Diabetic Neuropathy: A Clinical Overview. Current Diabetes Reviews, 2005, 1, 271-280.	1.3	11
190	Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale. Journal of Neuromuscular Diseases, 2015, 2, 301-311.	2.6	11
191	Disease activity in chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 2016, 369, 204-209.	0.6	11
192	Patientâ€reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. European Journal of Neurology, 2020, 27, 196-203.	3.3	11
193	Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis. European Journal of Neurology, 2020, 27, 2286-2291.	3.3	11
194	Thymoma pathology and myasthenia gravis outcomes. Muscle and Nerve, 2021, 63, 868-873.	2.2	11
195	Split-hand phenomenon in motor neuron diseases: Sonographic assesment of muscle thickness. Clinical Neurophysiology, 2020, 131, 1721-1725.	1.5	11
196	Association of social support with quality of life in patients with polyneuropathy. Journal of the Peripheral Nervous System, 2013, 18, 37-43.	3.1	10
197	Acute Intermittent Porphyria: A Report of 3 Cases with Neuropathy. Case Reports in Neurology, 2019, 11, 32-36.	0.7	10
198	Superiority of sonographic evaluation of contracted versus relaxed muscle thickness in motor neuron diseases. Clinical Neurophysiology, 2020, 131, 1480-1486.	1.5	10

#	Article	IF	Citations
199	Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107798.	2.3	10
200	Retrospective study on the safety of <scp>COVID</scp>â€19 vaccination in myasthenia gravis. Muscle and Nerve, 2022, 66, 558-561.	2.2	10
201	Diagnostic Tools for Diabetic Sensorimotor Polyneuropathy. Current Diabetes Reviews, 2006, 2, 353-361.	1.3	9
202	Evidence of smallâ€fiber neuropathy in neurofibromatosis type 1. Muscle and Nerve, 2019, 60, 673-678.	2.2	9
203	Prospective study of stress, depression and personality in myasthenia gravis relapses. BMC Neurology, 2020, 20, 261.	1.8	9
204	Performance of different criteria for refractory myasthenia gravis. European Journal of Neurology, 2021, 28, 1375-1384.	3.3	9
205	Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences, 2022, 49, 7-18.	0.5	9
206	Treatment Approaches for Atypical CIDP. Frontiers in Neurology, 2021, 12, 653734.	2.4	9
207	Telephone consultation for myasthenia gravis care during the COVID â€19 pandemic: Assessment of a novel virtual myasthenia gravis index. Muscle and Nerve, 2021, 63, 831-836.	2.2	9
208	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. PLoS ONE, 2015, 10, e0139674.	2.5	9
209	Characteristics of muscle cramps in patients with polyneuropathy. Neuromuscular Disorders, 2014, 24, 671-676.	0.6	8
210	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. PLoS ONE, 2015, 10, e0139689.	2.5	8
211	High-Dose Subcutaneous Immunoglobulin in Patients With Multifocal Motor Neuropathy. Journal of Infusion Nursing, 2017, 40, 305-312.	2.3	8
212	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. Clinical Neurophysiology, 2018, 129, 122-126.	1.5	8
213	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107397.	2.3	8
214	New insights into very-late-onset myasthenia gravis. Nature Reviews Neurology, 2020, 16, 299-300.	10.1	8
215	Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness. Journal of Neuromuscular Diseases, 2020, 7, 297-300.	2.6	8
216	The Perfect Clinical Trial. International Review of Neurobiology, 2016, 127, 27-41.	2.0	7

#	Article	IF	Citations
217	The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome. Clinical Neurophysiology, 2018, 129, 2239-2244.	1.5	7
218	Fasciculation frequency at the biceps <scp>brachii</scp> and brachialis muscles is associated with <scp>amyotrophic lateral sclerosis</scp> disease burden and activity. Muscle and Nerve, 2021, 63, 204-208.	2.2	7
219	Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience. Canadian Journal of Neurological Sciences, 2021, , 1-5.	0.5	7
220	Quantitative sonographic assessment of myotonia. Muscle and Nerve, 2018, 57, 146-149.	2.2	7
221	POEMS syndrome in a 24-year-old man associated with vitamin B12 deficiency and a solitary lytic bone lesion. , 1997, 20, 1454-1456.		6
222	How sensitive is the case definition for diabetic sensorimotor polyneuropathy to the use of different symptoms, signs, and nerve conduction parameters in Type 1 diabetes?. Diabetes Research and Clinical Practice, 2011, 92, e16-e19.	2.8	6
223	Choosing drugs for the treatment of diabetic neuropathy. Expert Opinion on Pharmacotherapy, 2015, 16, 1805-1814.	1.8	6
224	Study protocol for a pilot, randomised, double-blinded, placebo controlled trial of perineural local anaesthetics and steroids for chronic post-traumatic neuropathic pain in the ankle and foot: the PREPLANS study. BMJ Open, 2016, 6, e012293.	1.9	6
225	Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest. Clinical Neurophysiology, 2016, 127, 3294-3297.	1.5	6
226	Selective or predominant triceps muscle weakness in Africanâ€“American patients with myasthenia gravis. Neuromuscular Disorders, 2017, 27, 646-649.	0.6	6
227	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology, 2018, 90, e2034-e2041.	1.1	6
228	Ultrasound-Assisted Lumbar Puncture in a Neuromuscular Clinic has a High Success Rate and Less Pain. Canadian Journal of Neurological Sciences, 2019, 46, 79-82.	0.5	6
229	Emerging drugs for the treatment of myasthenia gravis. Expert Opinion on Emerging Drugs, 2021, 26, 259-270.	2.4	6
230	Gelsolin Familial Amyloidosis Peripheral Neuropathy in Canada: A Case Report. Canadian Journal of Neurological Sciences, 2015, 42, 353-355.	0.5	5
231	Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic. Canadian Journal of Neurological Sciences, 2017, 44, 577-588.	0.5	5
232	Recording Fewer Than 20 Potential Pairs With SFEMG May Suffice for the Diagnosis of Myasthenia Gravis. Journal of Clinical Neurophysiology, 2017, 34, 408-412.	1.7	5
233	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 424-428.	2.3	5
234	Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia. Blood Research, 2018, 53, 172.	1.3	5

#	Article	IF	Citations
235	Ischaemia due to a vascular malformation causing focal myositis. BMJ Case Reports, 2014, 2014, bcr2013202442-bcr2013202442.	0.5	5
236	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108134.	2.3	5
237	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	4
238	Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity. Canadian Journal of Neurological Sciences, 2019, 46, 735-741.	0.5	4
239	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. Renal Failure, 2019, 41, 427-433.	2.1	4
240	Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects. Canadian Journal of Neurological Sciences, 2019, 46, 337-341.	0.5	4
241	The utility of a single simple question in the evaluation of patients with nondiabetic polyneuropathy. Muscle and Nerve, 2020, 61, 526-529.	2.2	4
242	Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. Clinical Neurophysiology, 2021, 132, 226-231.	1.5	4
243	Dorsal versus ventral monofilament testing of the great toe for the identification of diabetic sensorimotor polyneuropathy. Diabetes Research and Clinical Practice, 2011, 93, e71-e73.	2.8	3
244	FcÎ³ Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2012, 14, 1-6.	0.7	3
245	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. Canadian Journal of Neurological Sciences, 2018, 45, 346-349.	0.5	3
246	Electrophysiological Responsiveness to Long-Term Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: Case Report. Case Reports in Neurology, 2020, 12, 40-44.	0.7	3
247	Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Clinical Neurophysiology, 2021, 132, 2184-2190.	1.5	3
248	Analysis of relapse by inflammatory Raschâ€built overall disability scale status in the <scp>PATH</scp> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2022, 27, 159-165.	3.1	3
249	Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. Neurodegenerative Disease Management, 2016, 6, 237-247.	2.2	2
250	GamunexÂ® in Guillain-BarrÃ© Syndrome: A Postmarketing, Retrospective, Observational Study. Canadian Journal of Neurological Sciences, 2017, 44, 711-717.	0.5	2
251	European Federation of Neurological Societies cutoff values significantly reduce creatine kinase sensitivity for diagnosing neuromuscular disorders. Muscle and Nerve, 2019, 60, 748-752.	2.2	2
252	Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders. Canadian Journal of Neurological Sciences, 2021, , 1-7.	0.5	2

#	Article	IF	Citations
253	Analgesic effect of perineural local anesthetics, steroids, and conventional medical management for trauma and compression-related peripheral neuropathic pain: a retrospective cohort study. Pain Reports, 2021, 6, e945.	2.7	2
254	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 839-850.	2.5	2
255	Pilot study of a novel transmembranous electromyography device for assessment of oral cavity and oropharyngeal muscles. Muscle and Nerve, 2022, 65, 303-310.	2.2	2
256	Orthostatic blood pressure changes and diabetes duration. Journal of Diabetes and Its Complications, 2022, 36, 108169.	2.3	2
257	An update on the use of immunoglobulins as treatment for myasthenia gravis. Expert Review of Clinical Immunology, 2022, 18, 703-715.	3.0	2
258	Current and future immunotherapy in myasthenia gravis. Future Neurology, 2009, 4, 745-759.	0.5	1
259	Response to Comment on Breiner et al. Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients? Diabetes Care 2014;37:1418â€“1424. Diabetes Care, 2014, 37, e242-e242.	8.6	1
260	Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment. Canadian Journal of Neurological Sciences, 2019, 46, 762-766.	0.5	1
261	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. Journal of Diabetes and Its Complications, 2019, 33, 547-549.	2.3	1
262	Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations. Journal of Clinical Neuromuscular Disease, 2019, 20, 165-172.	0.7	1
263	Important advances in neuromuscular research in 2019. Lancet Neurology, The, 2020, 19, 14-16.	10.2	1
264	Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy. Current Diabetes Reviews, 2021, 17, .	1.3	1
265	Sensory nerve area measurements in patients with diabetic neuropathy. Electromyography and Clinical Neurophysiology, 2001, 41, 59-63.	0.2	1
266	Excessive Daytime Sleepiness in Patients with Myasthenia Gravis. Journal of Neuromuscular Diseases, 2015, 2, 93-97.	2.6	1
267	Electrodiagnostic evaluation in diabetic neuropathy. , 2022, , 35-45.		1
268	Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy. Frontiers in Neurology, 2022, 13, 872762.	2.4	1
269	Diagnosis of Painful Diabetic Neuropathy. , 2013, , 27-34.		0
270	Infusing IVIG through Community Care Access Services in Patients with CIDP. Canadian Journal of Neurological Sciences, 2016, 43, 326-328.	0.5	0

#	Article	IF	Citations
271	Rare disease levels of evidence. Neurology, 2017, 89, 988-989.	1.1	0
272	High frequency of MGUS in DSP. Muscle and Nerve, 2018, 57, 1018-1021.	2.2	0
273	046â€...Efficacy and safety of intravenous immunoglobulin (IVIG) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A19.2-A19.	1.9	0
274	The complex association between pain and neuropathy. Muscle and Nerve, 2021, 63, 538-545.	2.2	0
275	Management of Myasthenia Gravis: Does Thymectomy Provide Benefit over Medical Therapy Alone?. , 2007, , 463-468.		0
276	THE SENSITIVITY AND SPECIFICITY OF SPLIT HAND INDEX USING MUSCLE SONOGRAPHY. Canadian Journal of Neurological Sciences, 2022, , 1-16.	0.5	0
277	Clinical profile and multidisciplinary needs of patients with neuromuscular disorders transitioning from paediatric to adult care. Neuromuscular Disorders, 2022, 32, 206-212.	0.6	0
278	Polyneuropathy Quality Measurement Set. Neurology, 2022, 98, 22-30.	1.1	0
279	Gastrointestinal Dysmotility as the First Manifestation of Myasthenia Gravis. Canadian Journal of Neurological Sciences, 0, , 1-7.	0.5	0